Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pramlintide in resectable cutaneous squamous cell carcinoma
NCT04252612Phase 1Withdrawn
- Sponsor
- Moffitt Cancer Center
- Start
- Jan 2020
- Primary completion
- Jun 2023
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, open-label trial of pramlintide in cutaneous squamous cell carcinoma (cSCC) (3 cohorts), sponsored by Moffitt Cancer Center. Primary endpoint: Participant Compliance at 14 days. Planned start Jan 2020; status: withdrawn.
02
Drugs
pramlintide
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on NCT04252612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04252612.